Contact:

At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992

At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672

or
General Inquiries
Kathy Waller
312.640.6696

RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) (www.regenerx.com), today announced that it will report fourth quarter and year end 2006 results before the market opens on Monday, April 2, 2007. Following the release and filing of the Form 10-K that morning, the company will conduct a conference call at 3:00 p.m. Eastern Time (2:00 p.m. Central Time) to discuss the results and its outlook for 2007.

The conference call will be accessible by telephone and through the Internet. Interested individuals are invited to access the call by dialing 800.811.8845. To participate on the webcast, log on to the company's website at www.regenerx.com or www.viavid.net 15 minutes before the call to download the necessary software.

For those unable to listen to the call live, a taped rebroadcast will be available beginning approximately two hours after completion of the live call on April 2, 2007 through April 9, 2007. To access the replay, dial 888-203-1112 and request reservation number 3491428. A replay of the call will also be available on the Internet at www.regenerx.com or www.viavid.net for 30 days.

About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore, RegeneRx is developing TB4 as the cornerstone of its therapeutic platform. The technology platform has many potential applications in both the pharmaceutical and consumer products sectors. RegeneRx holds nearly 60 world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, septic shock and several consumer product areas. RegeneRx is currently sponsoring three Phase 2 chronic dermal wound healing clinical trials and has additionally targeted ophthalmic and cardiac trials in 2007 as part of its ongoing clinical development program.

For more information please visit RegeneRx's web site at www.regenerx.com.

SOURCE: RegeneRx Biopharmaceuticals, Inc.

Back To 2007 Press Release Archives